137 related articles for article (PubMed ID: 4053491)
1. The pharmacokinetic and bactericidal characteristics of oral cefixime.
Brittain DC; Scully BE; Hirose T; Neu HC
Clin Pharmacol Ther; 1985 Nov; 38(5):590-4. PubMed ID: 4053491
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
Neu HC
Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
[TBL] [Abstract][Full Text] [Related]
3. [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
Toyonaga Y; Hatakeyama K; Yamori K; Sakaguchi N; Nakano K; Yamazaki M; Sugita M; Hori M
Jpn J Antibiot; 1992 Jan; 45(1):48-73. PubMed ID: 1495196
[TBL] [Abstract][Full Text] [Related]
4. [Fundamental and clinical studies on cefixime in pediatrics].
Iwai N; Shibata M; Mizoguchi F; Nakamura H; Katayama M
Jpn J Antibiot; 1986 Apr; 39(4):1087-105. PubMed ID: 3761539
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefixime, a new oral cephalosporin.
Fass RJ; Helsel VL
Chemioterapia; 1988 Dec; 7(6):365-8. PubMed ID: 3219746
[TBL] [Abstract][Full Text] [Related]
6. [Fundamental and clinical studies on cefixime (5% granules) in the pediatric field].
Toyonaga Y; Sugita M; Nakamura H; Joh K; Takahashi T; Kurosu Y; Hori M
Jpn J Antibiot; 1986 Apr; 39(4):1055-75. PubMed ID: 3761537
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
[TBL] [Abstract][Full Text] [Related]
8. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
Dan M; Poch F; Edelman A; Asherov J; Hafely H; Atzmon Y
J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
[TBL] [Abstract][Full Text] [Related]
9. [Fundamental and clinical studies on cefixime in the pediatric field].
Nakashima S; Hayakawa F; Nakashima T; Miyachi Y; Hakamada S; Kuno K
Jpn J Antibiot; 1986 Apr; 39(4):1076-86. PubMed ID: 3761538
[TBL] [Abstract][Full Text] [Related]
10. Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.
Bergeron MG; Turcotte A
Antimicrob Agents Chemother; 1986 Dec; 30(6):913-6. PubMed ID: 3545070
[TBL] [Abstract][Full Text] [Related]
11. Third generation oral cephalosporins: comparative in vitro kinetics.
Speciale A; Blandino G; Nicoletti G
J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability of cefixime in man.
Faulkner RD; Fernandez P; Lawrence G; Sia LL; Falkowski AJ; Weiss AI; Yacobi A; Silber BM
J Clin Pharmacol; 1988 Aug; 28(8):700-6. PubMed ID: 3216036
[TBL] [Abstract][Full Text] [Related]
14. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens.
Debbia EA; Marchese A; Pesce A; Saverino D; Schito GC
J Chemother; 1992 Jun; 4(3):131-44. PubMed ID: 1517806
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies of cefixime granules in pediatrics].
Nakazawa S; Sato H; Narita A; Nakazawa S; Suzuki H; Matsumoto K; Chikaoka H; Kamigaki M; Koido R; Niino K
Jpn J Antibiot; 1986 Apr; 39(4):1020-34. PubMed ID: 3761535
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and clinical effects of cefixime in pediatrics].
Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita S; Nishiyama T; Ishimoto K; Tominaga K; Yamashita F; Nagayama K
Jpn J Antibiot; 1986 Apr; 39(4):1177-200. PubMed ID: 3761546
[TBL] [Abstract][Full Text] [Related]
17. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.
Stone JW; Linong G; Andrews JM; Wise R
J Antimicrob Chemother; 1989 Feb; 23(2):221-8. PubMed ID: 2708180
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefixime (FK 027) for resistant gram-negative bacilli.
Smith SM; Eng RH
Chemotherapy; 1988; 34(6):455-61. PubMed ID: 3243091
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose.
Mamzoridi K; Kasteridou N; Peonides A; Niopas I
Pharmacol Toxicol; 1996 Jun; 78(6):417-20. PubMed ID: 8829204
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis.
Yamada T; Yokota Y; Ikeda F; Mine Y; Kitada T
Chemotherapy; 1992; 38(1):28-35. PubMed ID: 1618001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
